Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020890 | Journal of Neuroimmunology | 2011 | 7 Pages |
Abstract
Carbenoxolone (CBX) is a widely used gap-junction inhibitor. We have previously shown that treatment with CBX significantly delayed the onset of experimental autoimmune encephalomyelitis (EAE). However, the mechanism by which CBX delays the onset of EAE remains to be elucidated. Here, we show that CBX specifically inhibits the production of IL-23 by dendritic cells (DCs) and microglia in vitro. CBX treatment significantly reduced the population of Th17 cells in EAE mice. Furthermore, CBX downregulated the expression of IL-23 p19 via increased production of protein phosphatase 2A (PP2A). Thus, CBX may be an effective therapeutic strategy against Th17-mediated autoimmune diseases, such as multiple sclerosis.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Li Endong, Jin Shijie, Yoshifumi Sonobe, Ma Di, Li Hua, Jun Kawanokuchi, Tetsuya Mizuno, Akio Suzumura,